According to a new report published by Introspective Market Research, titled, Non-invasive Prenatal Testing (NIPT) Market by Product, Technology, End-User, and Region, The Global Non-invasive Prenatal Testing (NIPT) Market Size Was Valued at USD 5.65 Billion in 2023 and is Projected to Reach USD 17.35 Billion by 2032, Growing at a CAGR of 11.36%
The global Non-invasive Prenatal Testing (NIPT) market is gaining momentum as expectant parents and healthcare providers increasingly favor safer, more accurate genetic screening methods over invasive procedures. NIPT analyzes cell-free fetal DNA in maternal blood to detect chromosomal abnormalities such as trisomy 21, 18, or 13, reducing the risk associated with amniocentesis or chorionic villus sampling.
Compared to conventional prenatal testing methods, NIPT offers high sensitivity and specificity, minimal risk to the fetus, and earlier detection. Advances in sequencing technologies, bioinformatics, and laboratory workflows have improved turnaround times and cost efficiency.
This technology is increasingly integrated into standard prenatal care, especially in developed markets, fueled by rising maternal age, increased awareness of genetic disorders, reimbursement support, and the push for early, non-invasive diagnostics in obstetrics and gynecology.
The NIPT Market is segmented into Product, Technology, and End-User. By Product, the market is categorized into (Consumables & Reagents, Instruments, Services). By Technology, the market is categorized into (Next-Generation Sequencing (NGS), Microarray, PCR, Rolling Circular Amplification). By End-User, the market is categorized into (Hospitals, Diagnostic Laboratories, Research Centers).
One of the key growth drivers in the NIPT market is the increasing prevalence of chromosomal abnormalities coupled with rising maternal age globally. As more women delay childbirth, the risk of fetal aneuploidy increases, making reliable prenatal screening more critical. NIPT’s non-invasive nature and high accuracy have made it a preferred first-line screening tool in many healthcare systems. Moreover, growing awareness among patients and clinicians, along with favorable reimbursement policies in developed markets, is encouraging its adoption.
A major opportunity lies in expanding NIPT adoption in emerging markets through cost reduction, localized testing infrastructure, and partnerships with public health programs. Many developing regions have low penetration due to high costs, lack of awareness, and limited lab capacity. By developing lower-cost assays, decentralizing testing, and securing government or insurer support, NIPT providers can tap into large underserved populations, especially in Asia-Pacific, Latin America, and parts of Africa.
Non-invasive Prenatal Testing (NIPT) Market, Segmentation
The NIPT Market is segmented on the basis of Product, Technology, and End-User.
Product
The Product segment is further classified into Consumables & Reagents, Instruments, and Services. Among these, the Consumables & Reagents sub-segment accounted for the highest market share in 2024. Reagents and consumables are consumed in each test run (e.g., sequencing kits, sample prep reagents), making them recurring revenue drivers. Their critical role in test workflows and continual demand in high-volume labs support robust market share.
Technology
The Technology segment is further classified into Next-Generation Sequencing (NGS), Microarray, PCR, and Rolling Circular Amplification. Among these, the NGS sub-segment accounted for the highest market share in 2024. NGS is preferred because it offers comprehensive coverage, higher sensitivity, and ability to detect a broader range of chromosomal anomalies. Its scalability, decreasing costs, and improvements in data analysis pipelines make it the dominant technology in NIPT.
Some of The Leading/Active Market Players Are-
- Illumina, Inc. (USA)
- Natera, Inc. (USA)
- F. Hoffmann-La Roche Ltd. (Switzerland)
- PerkinElmer Inc. (USA)
- YourGene Health (UK)
- Myriad Women’s Health (USA)
- Agilent Technologies (USA)
- Bharat Genomics (India)
- Centogene N.V. (Germany)
- BGI Genomics (China)
- other active players.
Key Industry Developments
-
In March 2024, Natera received expanded regulatory approval in multiple European countries for its Panorama NIPT test to include microdeletion detection.
This expansion allows Natera to offer its Panorama test with added capability to screen for microdeletions (small chromosomal deletions) in addition to the standard trisomies. The regulatory approval enhances the value proposition of Panorama, positioning it as a more comprehensive screening option in Europe’s growing prenatal diagnostics market. It also helps Natera expand its footprint across Europe and appeal to providers seeking broader test panels. - In July 2023, Illumina acquired a startup developing AI-driven prenatal sequencing analytics to strengthen its NIPT data interpretation platform.
Illumina’s strategic acquisition enabled integration of advanced AI algorithms into its NIPT software, improving variant calling accuracy, reducing false positives, and optimizing report generation. This move deepens Illumina’s vertical integration across sequencing hardware, reagents, and informatics, enhancing competitive differentiation. It also accelerates development of precision analytics that can support more complex genomic interpretations in prenatal screening.
Key Findings of the Study
- Consumables & Reagents dominate due to recurring use in test workflows.
- NGS leads technology segmentation because of its sensitivity and breadth.
- Hospitals and diagnostic labs are key end-users driving demand.
- Growth is driven by increasing maternal age and awareness of genetic risks.
- Expansion into emerging markets via cost reduction is a critical opportunity.
